Flaws in the regulatory system are apparent, but how to rectify them remains unclear.
This is a preview of subscription content, log in via an institution to check access.
Related links
Rights and permissions
About this article
Cite this article
Frantz, S. How to avoid another 'Vioxx'. Nat Rev Drug Discov 4, 5–7 (2005). https://doi.org/10.1038/nrd1629
Issue Date:
DOI: https://doi.org/10.1038/nrd1629
- Springer Nature Limited
This article is cited by
-
Painkiller verdict shows mistrust of Merck
Nature (2005)
-
Drug safety on trial
EMBO reports (2005)
-
Vioxx may go back on sale after scraping past FDA panel
Nature (2005)
-
Monitoring the safety of licensed medicines
Nature Reviews Drug Discovery (2005)